(Panitumumab)Biosimilar Reference Antibody-GS40529

货号：GS40529

Panitumumab is a fully human IgG2κ monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It binds with high affinity to the extracellular domain of EGFR, blocking ligand (e.g., EGF, TGF‑α) binding and preventing receptor activation. This inhibits downstream signaling pathways (e.g., RAS/RAF/MAPK, PI3K/AKT) that drive tumor cell proliferation, survival, and metastasis. Panitumumab is approved for the treatment of wild‑type RAS (KRAS/NRAS) metastatic colorectal cancer (mCRC)—both as monotherapy after disease progression on fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, and in combination with chemotherapy for first‑line treatment. It is administered via intravenous infusion.